Carles Palacio

Carles Palacio

Auto-generated profile, based on publicly available information

Carles Palacio

Servei d'Hematologia, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AJAntonio Julià
Antonio Julià
AEAlba Erra
Alba Erra
CPCarles Palacio
Carles Palacio
CTCarlos Tomas
Carlos Tomas
XSXavier Sans
Xavier Sans
SMSara Marsal
Sara Marsal
TNF alpha blockade agents like infliximab are actually the treatment of choice for those rheumatoid arthritis (RA) patients who fail standard therapy. However, a considerable percentage of anti-TNF alpha treated patients do not show a significant clinical response. Given that new therapies for treatment of RA have been recently approved, there is a pressing need to find a system that reliably predicts treatment response. We hypothesized that the analysis of whole blood gene expression profiles of RA patients could be used to build a robust predictor to infliximab therapy. We performed microarray gene expression analysis on whole blood RNA samples from RA patients starting infliximab therapy (n = 44). The clinical response to infliximab was determined at week 14 using the EULAR criteria. Blood cell populations were determined using flow cytometry at baseline, week 2 and week 14 of treatment. Using complete cross-validation and repeated random sampling we identified a robust 8-gene predictor model (96.6% Leave One Out prediction accuracy, P = 0.0001). Applying this model to an independent validation set of RA patients, we estimated an 85.7% prediction accuracy (75–100%, 95% CI). In parallel, we also observed a significantly higher number of CD4+CD25+ cells (i.e. regulatory T cells) in the responder group compared to the non responder group at baseline (P = 0.0009). The present 8-gene model obtained from whole blood expression efficiently predicts response to infliximab in RA patients. The application of the present system in the clinical setting could assist the clinician in the selection of the optimal treatment strategy in RA.

23 February 2010 in Haematologica
Verified
Journal Article
Closed access
PDF file
IEI. Elorza
I. Elorza
CPC. Palacio
C. Palacio
JDJ. L. Dapena
J. L. Dapena
LGL. Gallur
L. Gallur
JTJ. S. de Toledo
J. S. de Toledo
CHC. D. de Heredia
C. D. de Heredia
Background The presence of minimal residual disease detected by polymerase chain reaction techniques prior to allogeneic hematopoietic stem cell transplantation has proven to be an independent prognostic factor for poor outcome in children with acute lymphoblastic leukemia. Design and Methods The aim of this study was to ascertain whether the presence of minimal residual disease detected by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation is related to outcome in children acute lymphoblastic leukemia. Minimal residual disease was quantified by multiparametric flow cytometry at a median of 10 days prior to hematopoietic stem cell transplantation in 31 children (age range, 10 months to 16 years) with acute lymphoblastic leukemia. Thirteen patients were transplanted in first remission. Stem cell donors were HLA-identical siblings in 8 cases and matched unrelated donors in 23. Twenty-six children received a total body irradiation-containing conditioning regimen. According to the level of minimal residual disease, patients were divided into two groups: minimal residual disease-positive (≥0.01%) (n=10) and minimal residual disease-negative (<0.01%) (n=21). Results Estimated event-free survival rates at 2 years for the minimal residual disease-negative and -positive subgroups were 74% and 20%, respectively (P=0.004) and overall survival rates were 80% and 20%, respectively (P=0.005). Bivariate analysis identified pre-transplant minimal residual disease as the only significant factor for relapse and also for death (P<0.01). Conclusions The presence of minimal residual disease measured by multiparametric flow cytometry identified a group of patients with a 9.5-fold higher risk of relapse and a 3.2-fold higher risk of death than those without minimal residual disease. This study supports the strong relationship between pre-transplantation minimal residual disease measured by multiparametric flow cytometry and outcome following allogeneic hematopoietic stem cell transplantation and concur with the results of previous studies using polymerase chain reaction techniques.

1 February 2013 in Fertility and Sterility
Verified
Journal Article
Closed access
JAJaume Alijotas-Reig
Jaume Alijotas-Reig
CPCarles Palacio-Garcia
Carles Palacio-Garcia
Elisa LlurbaElisa Llurba
Elisa Llurba
MVMiquel Vilardell-Tarres
Miquel Vilardell-Tarres

25 September 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JCJúlia Carabia
Júlia Carabia
CCCecilia Carpio
Cecilia Carpio
PAPau Abrisqueta
Pau Abrisqueta
IJIsabel Jiménez
Isabel Jiménez
NPNoelia Purroy
Noelia Purroy
MCMarta Crespo
Marta Crespo
Chronic lymphocytic leukemia (CLL) cells are highly dependent on microenvironment, being the BCR pathway one key player in this crosstalk. Among proteins participating, ZAP-70 enhances response to microenvironmental stimuli. MicroRNA-21 (miR-21) is overexpressed in diverse neoplasias including CLL, where it has been associated to refractoriness to fludarabine and to shorter time to progression and survival. To further elucidate the role of ZAP-70 in the biology of CLL, we studied its involvement in miR-21 regulation. MiR-21 expression was higher in CLL cells with high ZAP-70. Ectopic expression of ZAP-70 induced transcription of miR-21 via MAPK and STAT3, which subsequently induced downregulation of tumor suppressors targeted by miR-21. The co-culture of primary CLL cells mimicking the microenvironment induced ZAP-70 and miR-21 expression, as well as downregulation of miR-21 targets. Interestingly, the increase in miR-21 after co-culture was significantly impaired by ibrutinib, indicating that the BCR signaling pathway is involved in its regulation. Finally, survival of CLL cells induced by the co-culture correlated with miR-21 upregulation. In conclusion, stimuli from the microenvironment regulate miR-21 and its targeted tumor suppressor genes via a signaling pathway involving ZAP-70, thus contributing to the cytoprotection offered by the microenvironment particularly observed in CLL cells expressing ZAP-70.

13 October 2011 in American Journal of Reproductive Immunology
Verified
Journal Article
Closed access
PDF file
JAJaume Alijotas-Reig
Jaume Alijotas-Reig
CPCarles Palacio‐Garcia
Carles Palacio‐Garcia
IFImmaculada Farran‐Codina
Immaculada Farran‐Codina
MRMar Ruiz‐Romance
Mar Ruiz‐Romance
Elisa LlurbaElisa Llurba
Elisa Llurba
MVMiquel Vilardell‐Tarres
Miquel Vilardell‐Tarres

31 January 2011 in American Journal of Reproductive Immunology
Verified
Journal Article
Closed access
PDF file
JAJaume Alijotas-Reig
Jaume Alijotas-Reig
CPCarles Palacio-Garcia
Carles Palacio-Garcia
IFImmaculada Farran-Codina
Immaculada Farran-Codina
CZCristina Zarzoso
Cristina Zarzoso
LCLuis Cabero-Roura
Luis Cabero-Roura
MVMiquel Vilardell-Tarres
Miquel Vilardell-Tarres